Oncolytics Biotech (TSE:ONC) Insider Kirk Look Acquires 12,000 Shares of Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Kirk Look acquired 12,000 shares of the stock in a transaction dated Thursday, February 12th. The stock was bought at an average price of C$1.16 per share, for a total transaction of C$13,920.00. Following the purchase, the insider owned 171,465 shares of the company’s stock, valued at C$198,899.40. The trade was a 7.53% increase in their position.

Oncolytics Biotech Price Performance

TSE:ONC opened at C$14.90 on Friday. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. Oncolytics Biotech Inc. has a one year low of C$0.44 and a one year high of C$2.08. The company has a fifty day moving average price of C$14.90 and a 200 day moving average price of C$13.03. The stock has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. Analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.